reports
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update...
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the ...
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 (esreboxetine) for the management of fibromyalgia. FORWARD (Fibromyalgia Response with Esreboxetine Evaluated Using a Randomized Withdrawal Research Design) is a Phase 3, double-blind, placebo-controlled, multicenter,...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year ...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY® preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively SUNOSI® preliminary 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively SYMBRAVO® preliminary 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively...
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Su...
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (NDA)...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 i...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly se...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December: Piper Sandler 37th Annual Healthcare Conference Fireside Chat: Wednesday, December 3, 2025, at 4:00 p.m. ET in New York, NY BofA Securities CNS Therapeutics Virtual Conference 2025 Fireside Chat: Monday, December 8, 2025, at 11:40...
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positiv...
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has ente...
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and P...
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer’s disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWI...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium Fireside Chat: Thursday, November 6, 2025, at 9:50 a.m. ET in New York, NY Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET i...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along wit...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year’s theme for MIAW is “Building Community: Supporting Mental Well-being Together,” to highlight the import...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on ...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live...
Axsome Therapeutics Inc: 2 directors
A director at Axsome Therapeutics Inc sold after exercising options/sold 45,783 shares at 114.478USD and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pi...
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced six presentations across its broad portfolio of innovative neuroscience products and product candidates at Psych Congres...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: 2025 Wells Fargo Healthcare ConferenceFireside Chat: Wednesday, September 3, 2025, at 3:45 p.m. ET in Boston, MA Cantor Global Healthcare Conference 2025Fireside Chat: Thursday, September 4, 2025, at 1:00 p.m. ET in New York, NY M...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and ...
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million...
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing ...
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast its R&D Day event today at 11:00 AM Eastern NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorder...
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today. Herriot Tabute...
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on...
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live c...
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcomin...
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome’s singular, innovative late-stage CNS pipeline. At the event, physician key opinion leaders ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.